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Abstract
In 2016, the Immunization Technical Advisory Group of the South-East Asia Region (SEAR) 
endorsed a regional goal to achieve ≤1% prevalence of hepatitis B surface antigen (HBsAg) among 
5-year-old children by 2020. Chronic hepatitis B virus (HBV) infection is largely preventable with 
a birth dose of hepatitis B vaccine (HepB-BD) followed by two to three additional doses. We 
reviewed the progress towards hepatitis B control through vaccination in SEAR during 1992–
2015. We summarized hepatitis B vaccination data and reviewed the literature to determine the 
prevalence of chronic HBV infection pre- and post-vaccine introduction. We used a mathematical 
model to determine post-vaccine prevalence of HBsAg among 5 year olds in countries lacking 
national serosurvey data and estimated the impact of vaccination on disease burden. Regional 
coverage with three doses of hepatitis B vaccine (HepB3) increased from 56% in 2011 to 87% in 
2015. By 2016, 7 of 11 countries had introduced universal HepB-BD. Regional HepB-BD 
coverage increased from 9% in 2011 to 34% in 2015. In 2015, estimated HBsAg among 5 year 
olds was 1.1% with variability among countries. Myanmar (3.8%), Timor-Leste (2.7%), Indonesia 
(1.8%), and India (1%) had the highest prevalence of HBsAg. During 1992–2015, vaccination 
prevented approximately 16 million chronic HBV infections and 2.6 million related deaths. In 
2015, around 197,640 perinatal HBV infections occurred in SEAR with majority occurring in 
India (62%), Bangladesh (24%), and Myanmar (8%). Myanmar had the highest rate of perinatal 
chronic HBV infections at 16 per 1000 live births. Despite significant progress in the control of 
HBV, SEAR needs to secure political commitment for elimination and consider additional 
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strategies, such as promoting health facility births, universal birth dose administration, developing 
strong coordination between health sectors, and using alternative vaccine delivery methods, to 
improve HepB-BD coverage and subsequently achieve HBV control and elimination.
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1. Introduction
Globally, approximately 257 million persons are chronically infected with hepatitis B virus 
(HBV), and 686,000 die every year as a result of HBV-related liver cirrhosis and 
hepatocellular carcinoma (HCC) [1,2]. Chronic HBV infection develops in 90% of infants 
infected before 1 year of age, 25–50% of children infected during 1–5 years of age, and 5–
10% of persons infected after 5 years of age [3]. The World Health Organization (WHO) 
Strategic Advisory Groups of Experts (SAGE) recommends infants receive hepatitis B 
vaccine (HepB) at birth, ideally within 24 h, but administration up to 7 days after birth, 
followed by two or three additional doses can still be effective [3,4]. The Global Health 
Sector Strategy on Viral Hepatitis (GHSSVH) calls for a 30% reduction in new cases of 
chronic HBV infections (equivalent to 1% hepatitis B surface antigen [HBsAg] prevalence 
among children aged 5 years) by 2020 [5]. GHSSVH also calls for eliminating viral hepatitis 
by 2030 (equivalent to 0.1% HBsAg prevalence among children aged 5 years) [5].
In the WHO South-East Asia Region (SEAR), approximately 39 million persons are living 
with chronic HBV infection [1]. In 2016, the SEAR Immunization Technical Advisory 
Group (ITAG) endorsed a regional hepatitis B control goal to achieve a HBsAg prevalence 
of ≤1% among 5-year-old children by 2020 [6].
There has not been a comprehensive assessment of the current situation of hepatitis B 
vaccination and infection in the SEAR. We review the status of and progress towards 
hepatitis B control through vaccination in the SEAR, and we suggest strategies that would 
help the region reach the hepatitis B control goal by 2020 and HBV elimination by 2030.
2. Methods
For each country in SEAR, we compiled data on year of HepB introduction, HepB schedule, 
coverage with HepB-BD and with three doses of HepB (HepB3) [7,8]. HepB-BD coverage 
reported to WHO does not currently differentiate timely HepB-BD, defined as HepB-BD 
given within 24 h of birth, from birth dose given after 24 h. Therefore, we were not able to 
distinguish between timely and total HepB-BD coverage. We abstracted data on the 
proportion of women who attended at least one antenatal care visit, the institutional delivery 
rates, and the proportion of births attended by skilled birth attendant (SBA) [9]. We collected 
data on the number of live births in 2015 [10] and the number of surviving infants during 
1992–2015 [11].
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To evaluate the impact of HepB in SEAR, we conducted a comprehensive search of 
published literature and compiled available unpublished reports on prevalence of chronic 
HBV infection (i.e., percent of persons HBsAg positive) before and after vaccine 
introduction. To estimate pre-vaccine prevalence of HBsAg in each country, we included 
studies published from January 1995 to August 2016 with a sample size >100. We focused 
on studies reporting chronic HBV infection among children and young adults. However, in 
countries lacking these studies, adult populations were included. We excluded studies 
including populations with a known lower or higher prevalence of chronic HBV infection 
than the general population. We calculated the pre-vaccine regional prevalence of HBsAg 
among 5 year old children as a weighted average of HBsAg prevalence in each country 
adjusted by the number of surviving infants in 2000 from the World Population Prospects 
[11].
To estimate post-vaccine prevalence of HBsAg in each country, we included nationally 
representative serosurveys among children born after nationwide HepB introduction. For 
countries lacking nationally representative serosurveys, we used the hepatitis B 
mathematical model developed by Goldstein and colleagues to estimate the prevalence of 
HBsAg among 5-year-old children in 2015 [12], in accordance with the SEAR and 
GHSSVH indicators to measure cumulative incidence of chronic HBV infection at 5 years 
of age [5,6]. The Goldstein model requires country specific inputs, including number of 
surviving infants, vaccination coverage for HepB3 and HepB-BD, prevalence of HBsAg and 
hepatitis B e antigen (HBeAg) among women of childbearing age (WCBA), and prevalence 
of anti-hepatitis B core antibody (anti-HBc) at 5 years-of-age and ≥30 years. More details on 
the model are published elsewhere [12]. We determined post-vaccine regional prevalence of 
HBsAg among 5-year-old children in 2015 by calculating a weighted average of HBsAg 
prevalence in each country adjusted by the number of surviving infants in 2015 [11]. Based 
on vaccination coverage data during 2011–2015, reported literature findings on chronic 
hepatitis B prevalence in pregnant women and children, and the estimated post-vaccination 
hepatitis B prevalence in children, we provided recommendations and suggested strategies 
needed in the next 2–3 years to help each country reach the regional hepatitis B control and 
elimination goals.
We used the Goldstein model to estimate the total number of chronic HBV infections during 
the perinatal period and for all ages, and the number of chronic HBV infections averted and 
lives saved for each country from the year HepB was introduced to 2015. We compiled 
inputs of HepB-BD and HepB3 coverage [7], and the number of surviving infants [11] for 
each country from the year of HepB introduction to 2015. We used seroprevalence inputs 
from the most recent surveys and presumed they remained constant. When no data were 
available, we used the estimates published by Goldstein and colleagues [12]. Seroprevalence 
inputs used in the Goldstein model are summarized in the supplementary table. Using the 
Goldstein model, we calculated the number and rate of perinatal chronic HBV infections per 
1000 live births in each country in 2015.
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3. Results
3.1. Status of hepatitis B vaccination in the South-East Asia Region
Thailand was the first country in the region to introduce HepB in two provinces in 1988, and 
nationwide in 1992 (Table 1) [13]. Bhutan, Indonesia, and Maldives introduced HepB during 
the 1990s, while the remaining countries introduced it during the 2000s [7]. In Indonesia, 
HepB was introduced nationwide in 1997 following the Lombok Hepatitis B Immunization 
Project (1987–1991) [14]. HepB was introduced in a phased manner in Bangladesh (2003–
2005) and Nepal (2002–2004) [15]. In India, the vaccine was initially introduced in 14 
metropolitan cities in 2002, and nationally during 2011–2012 [16,17]. The majority of 
countries provide HepB as combined pentavalent vaccine (diphtheria, tetanus, pertussis, 
Haemophilus influenza type B, and hepatitis B vaccines) at 6, 10, and 14 weeks of age with 
one exception (Table 1) [7]. The overall regional HepB3 coverage increased from 56% in 
2011 to 87% in 2015 [8]. In 2015, seven countries achieved >90% HepB3 coverage 
(Bangladesh, Bhutan, DPR Korea, Maldives, Nepal, Sri Lanka, Thailand) while Myanmar 
and Timor-Leste had <80% coverage (Table 1) [7].
By 2015, six countries (Bhutan, DPR Korea, India, Indonesia, Maldives, and Thailand) had 
introduced universal HepB-BD vaccination (Table 2). In February 2016, Timor-Leste 
introduced universal HepB-BD. In September 2016, Myanmar introduced HepB-BD for 
institutional deliveries at hospitals with cold chain, and plans to expand to all deliveries in 
upcoming years. Myanmar first introduced HepB-BD during 2003–2005 when Gavi, the 
Vaccine Alliance, funded monovalent HepB introduction, however routine administration of 
HepB-BD stopped in 2009 after Gavi discontinued support for monovalent HepB [18]. All 
countries recommend HepB-BD within 24 h of birth except Indonesia which recommends 
HepB-BD within 7 days after birth [7]. In 2015, three of the six countries that provided 
universal birth dose achieved >90% coverage, while Indonesia (82%), Bhutan (78%), and 
India (44%) reported lower coverage (Table 2) [7]. The overall regional HepB-BD coverage 
increased from 9% in 2011 to 34% in 2015 (Table 2) [8].
India, Indonesia, Bangladesh, and Myanmar account for 95% of live births in the region 
(Table 2). In most of the countries, >70% of deliveries occurred in health facilities. Only 
22%, 36%, 37%, and 55% of births occurred in health facilities in Timor-Leste, Myanmar, 
Bangladesh, and Nepal, respectively, from which Timor-Leste is the only country that 
provides universal birth dose (Table 2) [9]. In Myanmar, however, 71% of home births are 
assisted by a SBA [9]. Births attended by SBA were lowest in Timor-Leste, Bangladesh, 
India, and Nepal (Table 2) [9].
In countries with high rates of home births, strategies have been developed to improve 
HepB-BD coverage. In Indonesia, informal notification of births using community members 
improved coordination with health professionals who provided the HepB-BD. Training of 
community health care workers and communication with mothers addressed cultural 
sensitivities around vaccination within the first week of life [14]. To mitigate hesitancy 
among healthcare workers (HCW) over opening vaccine vials for only 1 or 2 doses, India 
adopted an open vial policy reducing wastage by nearly 10% for monovalent HepB and 
pentavalent vaccines [16,19].
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Indonesia and Timor-Leste use a compact pre-filled auto-disable injection device (CPAD) to 
deliver the HepB-BD. Use of HepB-BD CPAD was more cost-effective than use of 
multidose vials, because it led to lower rates of vaccine wastage, [20] and it was easy to use 
by health workers with minimal training [14,21]. With proper training, use of CPAD in 
Indonesia was highly accepted by vaccinators, midwives, and mothers; 67% of midwives 
stated that CPAD was more practical and efficient to use than syringes [14,21]. In addition, 
Indonesia has been using HepB-BD outside of the cold chain (OCC) in hard to reach areas 
and has found no difference in seroconversion rates among CPAD stored OCC, CPAD stored 
in cold chain, and vials stored in cold chain [22]. HepB-BD coverage within 7 days post-
birth increased from 35% in 2003 to 82% in 2015, following implementation of national 
policy to use HepB-BD CPAD stored OCC in Indonesia [7].
Despite these strategies, countries reported challenges in providing timely HepB-BD. In a 
2009 HepB-BD assessment covering five states in India, vaccine stock-outs were reported 
and only a small proportion of infants were vaccinated within 24 h of birth [16]. In addition, 
incomplete recording and poor reporting of timely HepB-BD administration were found in 
both Indonesia and India [14,16].
3.2. Prevalence of chronic hepatitis B virus infection pre- and posthepatitis B vaccine 
introduction
Nationally representative pre- and post-hepatitis B vaccine introduction impact serosurveys 
were conducted in Bangladesh, Nepal, and Thailand. A decrease in HBsAg prevalence post-
vaccine introduction was found in all three countries (Table 3). In Bangladesh, a study 
conducted in 2012 reported HBsAg prevalence of 1.3% among children born before (10 
years old) and 0.05% among those born after (5 years old) HepB introduction [unpublished 
report]. In Nepal, in 2012, HBsAg prevalence was 0.28% among 10–12 year old children 
born before vaccine introduction and 0.13% among 5–6 year old children born after vaccine 
introduction [15]. HepB has been available in Thailand for over 25 years, and the most 
recent survey conducted in 2014 found a 0.3% prevalence of HBsAg among 5–10 year old 
children [13].
For five countries in SEAR (Bhutan, India, Indonesia, Myanmar and Sri Lanka), estimates of 
HBsAg seroprevalence were compiled from national or subnational serosurveys conducted 
before HepB introduction [23–30] (Table 3). There were no available data on HBsAg 
prevalence pre-vaccine introduction in DPR Korea, Maldives, and Timor-Leste. For these 
eight countries which lacked national post-vaccine impact serosurveys, we estimated 
prevalence of HBsAg among 5–6 year old children in 2015 using the Goldstein model.
In Bhutan, HBsAg prevalence decreased from 5.2% in mid-1990s among 1–12 year old 
children [23] to 0.4% in 2015 among 5-year-old children. Of note, Bhutan is conducting a 
national serosurvey in the general population that will evaluate the impact of HepB among 
children [1]. Based on non-representative serosurveys conducted in a few states, pre-vaccine 
HBsAg prevalence ranged from 1.2% to 5.7% in India [24–26] and 4.6% to 15.7% in 
Indonesia [27–29] among children and young adult populations (Table 3). We estimated 
post-vaccine introduction prevalence of HBsAg among children aged 5 years in 2015 at 
1.0% and 1.8% in India and Indonesia, respectively. In Myanmar and Sri Lanka, model 
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estimated post-vaccine HBsAg prevalence among 5 year olds was 3.8% and 0.8%, 
respectively (Table 3). We estimated the post-vaccine introduction prevalence of HBsAg 
among 5 year olds in DPR Korea, Maldives and Timor-Leste at 0.8%, 0.2% and 2.7%, 
respectively (Table 3).
The overall estimated regional prevalence of chronic HBV infection among 5-year-old 
children decreased from 3.9% in the prevaccine era to 1.1% in 2015, a 72% reduction.
3.3. Impact of hepatitis B vaccination on total number of chronic HBV infections and 
associated deaths
During 1992–2015, the total annual number of chronic HBV infections in the SEAR 
decreased significantly, as HepB3 and HepB-BD coverage increased (Fig. 1). In the region, 
chronic HBV infections declined from 2,366,129 in 1992 to fewer than 568,896 in 2015, a 
76% reduction. Similarly, the number of HBV-related deaths decreased by 76% during this 
period, from nearly 376,000 deaths in 1992 to approximately 89,000 deaths in 2015. During 
1992–2015, 16 million cases of chronic HBV infection were prevented through 
immunization, thereby averting 2.6 million hepatitis B related deaths in the region (Table 3). 
The most populous countries in the region, India and Indonesia, have averted nearly 13 
million chronic infections and 2 million deaths combined since vaccine introduction.
3.4. Number of perinatal chronic hepatitis B infections
In 2015, based on model estimates, a total of 197,640 perinatal chronic HBV infections 
occurred in SEAR. Of these infections, 122,301 (62%) occurred in India, 48,400 (24%) in 
Bangladesh, 16,384 (8%) in Myanmar, and 6266 (3%) in Indonesia (Fig. 2). The highest 
rates of perinatal chronic HBV infections occurred in Myanmar (16 per 1000 live births) and 
Bangladesh (15 per 1000 live births). India had approximately 5 cases and Indonesia had 1 
case of perinatal chronic HBV infection per 1000 live births. Thailand had the lowest rate 
(0.48 per 1000 live births) followed by the Maldives (0.55 per 1000 live births) (Fig. 2).
4. Discussion
This paper documents the remarkable achievements in the SEAR in controlling chronic 
HBV infection. We estimated the 2015 regional prevalence of HBsAg among 5-year-old 
children at 1.1%, which highlights SEAR is on the way to meeting to the regional hepatitis B 
control goal of ≤1% by 2020. This estimate is within the 95% confidence interval (CI) of 
recently reported modeling data that estimated HBsAg prevalence at 0.7% (95% CI: 0.5–
1.6%) among children aged <5 years in SEAR [1]. We chose to estimate prevalence among 
children aged 5 years because it is the indicator for the SEAR hepatitis B control goal and 
the GHSSVH. In addition, 5-year-old children have passed through the highest risk period 
for acquiring chronic HBV infection.
Despite the significant progress, additional efforts are required to increase HepB3 coverage 
and targeted strategies, are needed to increase HepB-BD coverage to ultimately achieve 
HBV control by 2020 and elimination by 2030 [5]. Based on the findings in this review, we 
highlight the specific strategies needed to reach the hepatitis B regional and global goals 
depending on the country’s situation in the following paragraphs and in Table 3.
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Bangladesh, Nepal, and Sri Lanka are the remaining countries in SEAR without HepB-BD 
in their immunization schedule. These countries should assess if HepB-BD introduction is a 
relevant strategy considering their epidemiological situation and the global goals of HBV 
elimination by 2030 [5]. In Sri Lanka, the prevalence of HBsAg among children is <1%; 
antenatal and delivery care are nearly universal, thus high coverage with HepB-BD could be 
achieved. In Nepal, the prevalence of HBsAg among children is also <1%. However, 
subnational studies showed geographic variability in HBsAg prevalence ranging from 6.6% 
in the Surkhet Valley to 7.3% in the Manang region [31]. Targeted HepB-BD introduction in 
certain geographical areas might be needed. In Bangladesh, our model seroprevalence 
estimates differed from HBsAg prevalence reported in the 2012 national serosurvey. The 
inputs for the model were from the data reported in the national serosurvey, which limits the 
bias of modelled estimates. Further, a recent review found most HBV infections in 
Bangladesh occur in childhood with an estimated 4.2% HBsAg prevalence among children 
in 2011 [32]. Based on model estimates, Bangladesh had a high number of perinatal 
infections per year (48,400) and a rate of 15 perinatal infections per 1000 live births (Fig. 2). 
Bangladesh needs more evidence to validate HBsAg prevalence among children and might 
need to consider introducing HepB-BD.
Timely HepB-BD administration should be easy to achieve in countries with high rates of 
health facility (HF) births. However, India, which had ≥70% of births in HF, reported HepB-
BD coverage <50%. SEAR countries should consider adopting strategies proven successful 
in the Western Pacific Region (WPR) to improve timely HepB-BD coverage. These include 
adding HepB-BD to routine immunization registers and cards, training and supervision of 
HCWs on reporting HepB-BD administration, and verifying vaccine stocks in the delivery 
wards. Furthermore, instituting standing orders assigning the responsibility of HepB-BD 
administration to the person delivering the infant would avoid confusion among HCWs, 
increase opportunities for infant vaccination, and increased timely HepB-BD coverage [33–
35].
In countries with low rates of HF births, such as Bangladesh, Myanmar, Nepal, and Timor-
Leste, several approaches could be implemented to improve timely HepB-BD coverage. 
Promoting institutional deliveries through provision of financial incentives and encouraging 
parents to deliver in HF led to an increase in timely HepB-BD coverage in Cambodia and 
China [33,34]. ANC visits could be used as an opportunity to promote HF births and educate 
mothers on timely HepB-BD. This strategy relies on strong coordination and collaboration 
between MCH and immunization services [33,34,36]. In addition, availability of SBA in HF 
is vital to ensure adequate care and timely HepB-BD coverage. In India, while 79% of 
deliveries are institutional, skilled personnel attend only 52% of deliveries, which did not 
improve care [37]. Therefore, India needs to establish a cadre of SBA to improve maternal 
and neonatal health and timely HepB-BD coverage.
Countries with a low proportion of HF births should improve timely HepB-BD coverage 
among home births and births outside HF. Currently, Myanmar provides HepB-BD for HF 
births, which account for 36% of total births. This strategy will not be sufficient to reduce 
chronic HBV infection given the high number and rate of perinatal infections, and an 
estimated HBsAg prevalence of >3% among 5-year-old children. Therefore, Myanmar 
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should expand HepB-BD administration outside HF. This should be feasible since 70% of 
births are attended by SBA [9], and midwives are responsible for routine immunization 
services. Timor-Leste has low HF delivery and SBA rates, which could affect timely HepB-
BD administration. Educating parents on the importance of timely HepB-BD during ANC 
visits and through community health volunteers were successful in China to improve HepB-
BD coverage among home births [34]. In Lao PDR, providing cell phones to village health 
volunteers to notify health workers of a labor or a recent delivery increased HF deliveries by 
13% and improved HepB-BD coverage by a median of 57% [38]. In Viet Nam, timely 
HepB-BD was higher (90–97%) in areas with community volunteers tracking and notifying 
HCWs of births compared to other areas (52%) [39]. Preparing combined microplans for 
routine immunization and MCH activities contributed to an increase in HepB-BD coverage 
in China [34]. Hence, countries in SEAR should apply these strategies to make sure all 
children are protected against HBV, irrespective of birth location.
Because HepB is the only vaccine that should be given within 24 h of birth, lack of cold 
chain can limit access to and provision of the vaccine. Use of HepB-BD outside the cold 
chain (OCC) is another strategy used by countries to reach home births or births occurring in 
facilities without proper cold chain storage. WHO SAGE supports countries that choose to 
pursue an OCC policy with monovalent hepatitis B vaccine, however if a policy is adopted, 
the WHO Immunization in Practices Advisory Committee (IPAC) recommendations for 
OCC and controlled temperature chain use of vaccines should be followed [3,4]. HepB from 
several manufacturers has been shown to be heat stable and able to withstand exposure to 
temperatures as high as 37 °C up to one month [4]. In Lao PDR, HepB-BD coverage 
improved by a median of 27% in districts with an OCC policy compared to no change in 
districts without an OCC policy [40]. In Viet Nam, coverage of HepB-BD administered 
within 3 days of birth improved from 45% to 89% when HepB was stored OCC, and 
seroconversion rates were similar to vaccines stored in the cold chain [41]. In Indonesia, use 
of HepB CPAD OCC contributed to significant increase in coverage and ability to reach 
home births especially in areas that lacked SBA [14,21]. Use of HepB CPAD OCC improved 
timely HepB-BD coverage and was widely accepted in pilot studies conducted in China and 
Papua New Guinea [33,36]. For countries with high proportion of home births or suboptimal 
cold chain, use of HepB-BD OCC in monovalent single dose vials or in CPAD might need to 
be considered to improve timely HepB-BD and promote the introduction of HepB-BD.
For some countries, another challenge to introduction and use of HepB-BD is the cost of a 
separate monovalent HepB. Monovalent HepB was funded by Gavi, the Vaccine Alliance, 
starting in 2001 but in 2005, Gavi discontinued monovalent HepB support and supported 
only combination vaccines [42]. Among the remaining four countries in SEAR without 
universal HepB-BD, all currently or previously have received Gavi support. In a recent 
WHO survey, vaccine cost was cited as a major obstacle to HepB-BD introduction although 
the cost of a single dose vial of HepB is only $0.20 [43,44]. Moving forward, strong political 
commitment and advocacy for government budget allocation will be necessary. In the WPR, 
countries continued to administer HepB-BD by identifying national funds or donor support 
after Gavi funding for monovalent HepB vaccine discontinued [33].
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Our review has shown that several SEAR countries have not conducted nationally 
representative hepatitis B serosurveys among children. In India and Indonesia, a number of 
studies focused on one area or state. DPR Korea, Timor Leste, and Maldives have no 
serosurvey data. Countries must now document the seroprevalence of chronic HBV infection 
by conducting nationally representative serosurveys among children at least 5 years of age 
[45], and monitor vaccination coverage as the region works towards reaching the hepatitis B 
control target by 2020 and ultimately elimination by 2030.
A major limitation was the lack of nationally representative data in several countries and the 
inability to assess timeliness of HepB-BD. We used a mathematical model, which relies 
heavily on the quality of input data, to estimate the current seroprevalence of HBsAg among 
5-year-old children. The Goldstein model does not consider the effects of herd immunity, 
immunity from incomplete vaccination, or delayed HepB-BD vaccination. Given the 
inability of current WHO/UNICEF coverage estimates to report timely HepB-BD, the model 
assumed HepB-BD coverage to be timely. The effectiveness of HepB-BD in prevention of 
perinatal transmission is highest if given within 24 h of birth and decreases gradually 
afterwards [3]. Given this limitation, we might have underestimated HBsAg prevalence if 
countries reported untimely HepB-BD. For Bangladesh, Nepal, and Thailand, we were able 
to compare post-vaccination estimates generated from the model to the estimates from 
national serosurveys. In Thailand, the model estimated a lower post-vaccination prevalence 
of HBsAg (0.05%) than the estimates from the most recent serosurvey (0.3%), which does 
not align with the conservative nature of the model. These results demonstrate the variability 
of model generated data, and reemphasize the need for countries to conduct well-designed 
nationally representative serosurveys.
Despite these limitations, this paper fills the gap in reporting the status of and progress 
towards hepatitis B control in the SEAR, and it provides baseline achievements that can be 
tracked. The region has made considerable progress towards chronic HBV prevention 
through vaccination; however, additional work is needed. Strong political commitment and 
secured vaccine financing in the region and among member states will be essential, in order 
to prioritize HBV prevention, reach the control goal by 2020, and subsequently elimination 
by 2030 [5]. Various strategies such as promoting health facility births, strong MCH and EPI 
coordination, and using alternative vaccine delivery methods could be used to improve 
HepB-BD and HepB3 coverage. Clear policies and guidelines communicated to all sectors 
involved in immunization will reduce missed opportunities. Assessing vaccine impact and 
estimating disease burden among children aged 5 years is needed as countries move towards 
verification of the achievement of the hepatitis B control goal.
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Fig. 1. 
Hepatitis B vaccination coverage and annual number of chronic hepatitis B virus (HBV) 
infections – World Health Organization (WHO) South-East Asia Region, 1992–2015. HBV: 
hepatitis B virus; HepB: hepatitis B vaccine; HepB3: 3-dose series of Hepatitis B vaccine; 
HepB-BD: Hepatitis B vaccine birth dose.
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Fig. 2. 
Estimated number* and rates of perinatal chronic hepatitis B virus (HBV) infections by 
hepatitis B vaccine birth dose coverage – World Health Organization (WHO) South-East 
Asia Region, 2015. *Numbers of perinatal chronic HBV infections are shown next to the 
name of the country in the figure.
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